Health Secretary RFK Jr. is expected to announce the approval of compounding pharmacies for peptide production, a move that could reshape the wellness industry.
Peptides have seen a surge in popularity among consumers, although there is limited data supporting their efficacy and safety.
The decision, set for March 31, 2026, will likely influence the regulatory landscape and operational frameworks of compounding pharmacies, impacting their capacity to meet rising demand.